What is Promise Bio?
Promise Bio operates at the intersection of computational biology and proteomics, providing a cloud-native AI platform that transforms raw mass-spectrometry data into actionable epiproteomic insights. By removing the inherent biases often found in traditional analytical workflows, the company enables researchers to identify novel biomarkers and therapeutic targets with greater precision. Its market position is bolstered by a unique collaborative model that bridges the gap between cutting-edge Israeli technological innovation and the rigorous requirements of global pharmaceutical R&D. The company's focus on epiproteomics—the study of protein modifications—represents a high-growth niche within the broader biotech sector, offering a scalable solution for drug discovery and personalized healthcare applications.
How much funding has Promise Bio raised?
Promise Bio has raised a total of $8.3M across 1 funding round:
Angel/Seed
$8.3M
Angel/Seed (2024): $8.3M with participation from Pfizer, Awz Ventures, AION Labs, Israel Innovation Authority, and AstraZeneca
Key Investors in Promise Bio
Pfizer
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve health outcomes and enhance quality of life.
AION Labs
AION Labs is a first-of-its-kind Venture Studio built by global pharma and technology leaders to create and adopt AI technologies that transform the process of drug discovery.
Israel Innovation Authority
The Innovation Authority is responsible for driving, investing in, and developing Israel's technological innovation, supporting entrepreneurs and startups in the high-tech sector.
What's next for Promise Bio?
With the successful closure of this major strategic investment, Promise Bio is well-positioned to scale its computational infrastructure and broaden its commercial reach. The company's roadmap likely includes the expansion of its AI model training sets and the establishment of deeper partnerships with its existing pharmaceutical backers to validate its platform in clinical settings. As the firm continues to refine its epiproteomic analysis capabilities, it will likely focus on optimizing its cloud-based delivery model to support high-throughput data processing for global research institutions. The strategic alignment with industry giants suggests a clear trajectory toward becoming an essential component of the modern drug development pipeline, potentially setting the stage for future commercialization milestones or further institutional financing rounds.
See full Promise Bio company page
